BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17933720)

  • 1. Tropism switch in patients infected with HIV-1 and its clinical implications for the treatment with CCR5-receptor inhibitors.
    Arastéh K; Stocker H
    Eur J Med Res; 2007 Oct; 12(9):397-402. PubMed ID: 17933720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of HIV-1 coreceptor tropism in clinical practise.
    Foeglein A; Walter H
    Eur J Med Res; 2007 Oct; 12(9):473-82. PubMed ID: 17933729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epidemiology of HIV coreceptor tropism.
    Hoffmann C
    Eur J Med Res; 2007 Oct; 12(9):385-90. PubMed ID: 17933718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
    Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G
    Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic coreceptor analysis.
    Sierra S; Kaiser R; Thielen A; Lengauer T
    Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR4-tropic HIV-1 suppresses replication of CCR5-tropic HIV-1 in human lymphoid tissue by selective induction of CC-chemokines.
    Ito Y; Grivel JC; Chen S; Kiselyeva Y; Reichelderfer P; Margolis L
    J Infect Dis; 2004 Feb; 189(3):506-14. PubMed ID: 14745709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection.
    Moyle GJ; Wildfire A; Mandalia S; Mayer H; Goodrich J; Whitcomb J; Gazzard BG
    J Infect Dis; 2005 Mar; 191(6):866-72. PubMed ID: 15717260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR5 antagonists: a new tool in fighting HIV.
    Jülg B; Goebel FD
    J HIV Ther; 2005 Dec; 10(4):68-71. PubMed ID: 16519245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
    Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV coreceptor phenotyping in the clinical setting.
    Low AJ; Swenson LC; Harrigan PR
    AIDS Rev; 2008; 10(3):143-51. PubMed ID: 18820716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4.
    Owen A; Chandler B; Bray PG; Ward SA; Hart CA; Back DJ; Khoo SH
    J Virol; 2004 Nov; 78(21):12022-9. PubMed ID: 15479841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pouncing on the chemokine receptor Chimera.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1997 Aug; 3(8):13-24. PubMed ID: 11364629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6.
    Grivel JC; Ito Y; Fagà G; Santoro F; Shaheen F; Malnati MS; Fitzgerald W; Lusso P; Margolis L
    Nat Med; 2001 Nov; 7(11):1232-5. PubMed ID: 11689888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
    Princen K; Schols D
    Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses.
    Wolinsky SM; Veazey RS; Kunstman KJ; Klasse PJ; Dufour J; Marozsan AJ; Springer MS; Moore JP
    Virology; 2004 Oct; 328(1):19-29. PubMed ID: 15380354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
    Soulié C; Marcelin AG; Ghosn J; Amellal B; Assoumou L; Lambert S; Duvivier C; Costagliola D; Katlama C; Calvez V
    AIDS; 2007 Oct; 21(16):2243-5. PubMed ID: 18090053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
    Hirsch MS; Günthard HF; Schapiro JM; Brun-Vézinet F; Clotet B; Hammer SM; Johnson VA; Kuritzkes DR; Mellors JW; Pillay D; Yeni PG; Jacobsen DM; Richman DD
    Clin Infect Dis; 2008 Jul; 47(2):266-85. PubMed ID: 18549313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CCR5 antagonists: a new class of antiretrovirals].
    Peytavin G; Calvez V; Katlama C
    Therapie; 2009; 64(1):9-16. PubMed ID: 19463248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.